FDA PCAC July 2026: 29 Days Out — What Researchers Need to Know Before the Hearing

The FDA Pharmacy Compounding Advisory Committee (PCAC) convenes on July 23–24, 2026 — 29 days from today — to issue recommendations on 503A bulk drug substance status for seven peptide compounds: BPC-157, TB-500, KPV, MOTS-c, DSIP, Semax, and Epitalon. The committee's recommendations will directly affect whether 503A compounding pharmacies may continue to prepare these compounds in patient-specific formulations. This article summarizes what the PCAC will evaluate, what outcome scenarios look like for each compound, and where to find the primary research record for each one.

Research reference only. This article covers the regulatory status of peptide compounds for informational purposes. Nothing here constitutes medical or legal advice.

Why this hearing matters

Under Section 503A of the Federal Food, Drug, and Cosmetic Act, traditional compounding pharmacies may use bulk drug substances — active ingredients that are not themselves FDA-approved finished drug products — only if those substances appear on a designated 503A Bulks List, or are under active review for it. The PCAC advises FDA on which nominations should be approved, declined, or conditionally approved. A negative PCAC recommendation does not automatically remove a compound from the 503A track, but it signals the regulatory direction FDA is likely to formalize in the following months.

For the seven compounds on the July 2026 agenda, this hearing represents the most significant regulatory event since their initial nominations were filed. The outcomes will affect:

• Compounding pharmacy availability in the United States
• Research supply chains dependent on 503A-compounded material
• The broader regulatory precedent for synthetic peptides in the 503A framework

The seven compounds: where each one stands

BPC-157 — highest-profile compound on the agenda

BPC-157 (Body Protective Compound-157) is a synthetic pentadecapeptide with over 30 years of preclinical literature, primarily from the Sikiric laboratory at the University of Zagreb, documenting tissue repair, cytoprotective, and angiogenic activity across gastrointestinal, musculoskeletal, and neurological models. It has no FDA-approved commercial equivalent.

The compound enters the July 2026 PCAC review with an active Phase 2 clinical trial underway: NCT07437547, which enrolled subjects with acute hamstring injuries in February 2026 — the first randomized controlled trial of BPC-157 in human subjects to reach Phase 2. This trial does not affect the PCAC review timeline but constitutes the strongest evidence signal BPC-157 has had at any prior regulatory juncture.

Search volume for BPC-157 terms has grown steadily in 2026; our BPC-157 Phase 2 trial coverage has generated more search impressions than any other page on this site — a signal of high researcher and clinician interest entering this hearing.

Full PCAC coverage: BPC-157 FDA PCAC July 2026: 503A Research Access Analysis
Library profile: BPC-157 compound page

TB-500 — preclinical record vs. WADA prohibited status

TB-500 is a synthetic analogue of Thymosin Beta-4, investigated for angiogenic and tissue-repair properties in preclinical models. It shares many mechanistic features with BPC-157 — VEGF upregulation, actin binding, angiogenesis — but has a substantially thinner published clinical evidence base. A 2026 narrative review confirmed the preclinical profile while noting that human orthopedic data are lacking and that TB-500 remains a WADA-prohibited substance in competitive sports contexts (S2 class).

WADA prohibition is not an FDA determination, but it may influence how the PCAC weighs the risk-benefit profile of 503A access: prohibited status signals the compound's appeal beyond compounding's intended patient-specific clinical use.

Full PCAC coverage: TB-500 FDA PCAC July 2026: 503A Research Access Analysis
Preclinical record: TB-500 FDA PCAC Review: The Preclinical Evidence Record
Comparison: TB-500 vs. BPC-157: Mechanism, Evidence, and Research Overlap
Library profile: TB-500 compound page

KPV — tripeptide with melanocortin receptor data

KPV (Lysine-Proline-Valine) is an α-MSH tripeptide fragment studied for melanocortin receptor signaling and anti-inflammatory properties. It is one of the less clinically documented compounds on the July agenda, with evidence concentrated in preclinical inflammatory bowel disease models and in vitro melanocortin signaling studies. A 2026 critical review grouped KPV with other synthetic peptide fragments appearing in performance-enhancement contexts, noting regulatory bodies' detection challenges due to structural similarity to endogenous sequences.

Full PCAC coverage: KPV FDA PCAC July 2026: 503A Research Access Analysis
Library profile: KPV compound page

MOTS-c — mitochondria-derived metabolic peptide

MOTS-c is a 16-amino acid peptide encoded within the 12S rRNA region of the mitochondrial genome — a peptide produced by mitochondria themselves rather than the nuclear genome. It activates AMPK-dependent metabolic signaling, improves insulin sensitivity, and has been studied in cardiac metabolic aging and exercise physiology contexts. A 2026 clinical study measured endogenous serum MOTS-c levels in adolescent populations with metabolic conditions, reflecting broadening clinical interest beyond preclinical models. MOTS-c has no FDA-approved equivalent.

MOTS-c is also among the compounds covered in our Peptides for Cardiovascular Research overview, where its role in cardiac AMPK axis research is covered alongside SS-31, VIP, and humanin.

Full PCAC coverage: MOTS-c FDA PCAC July 2026: 503A Research Access Analysis
Library profile: MOTS-c compound page

DSIP — neuropeptide under the oldest nomination

DSIP (Delta Sleep-Inducing Peptide) was first characterized in 1974 and has been studied for neuroendocrine regulatory effects including cortisol modulation, LH secretion timing, and sleep architecture. Its compounding nominations predate the modern 503A review process, making it one of the oldest continuously nominated neuropeptides on the bulks list docket. No commercial equivalent exists in the United States.

Full PCAC coverage: DSIP FDA PCAC July 2026: 503A Research Access Analysis
Library profile: DSIP compound page

Semax — approved in Russia, investigational in the United States

Semax is a synthetic heptapeptide derived from ACTH(4–7) that is approved for medical use in Russia for ischemic stroke and cognitive impairment indications. In the United States it is investigational, with no approved equivalent, making 503A compounding its primary domestic access channel. Preclinical Alzheimer's research published in 2026 documented BDNF upregulation and amyloid plaque reduction in transgenic mouse models at 10-week treatment durations (PMID 41479572). Its established international regulatory approval profile provides supporting data for the nomination argument, while the absence of U.S. clinical trials represents the primary regulatory gap.

Full PCAC coverage: Semax FDA PCAC July 2026: 503A Research Access Analysis
Comparison: Semax vs. Selank: Neuropeptide Comparison
Library profile: Semax compound page

Epitalon — telomerase-activating tetrapeptide

Epitalon (Ala-Glu-Asp-Gly) is a synthetic tetrapeptide derived from pineal gland preparations, studied primarily for telomerase activation through hTERT upregulation. A 2025 cell biology study demonstrated dose-dependent telomere length extension in both normal and cancer cell lines (PMID 41240216). There is no FDA-approved commercial equivalent. Its 503A eligibility rests entirely on the PCAC review outcome — a negative recommendation would effectively end domestic compounding access in the absence of an IND-based clinical trial supply channel.

Full PCAC coverage: Epitalon FDA PCAC July 2026: 503A Research Access Analysis
Library profile: Epitalon compound page

Outcome scenarios

The PCAC can recommend one of three outcomes for each compound:

Recommendation for inclusion on the 503A Bulks List: The compound may continue to be used by 503A compounding pharmacies. This is the outcome nominees are seeking. It requires the committee to find adequate evidence of clinical need, a reasonable basis for use in compounding, and no demonstrable safety concerns that would preclude it.

Recommendation against inclusion: The compound would be ineligible for use in 503A preparations. FDA is not bound by PCAC recommendations but typically follows them. Compounders holding existing formulations would face a phase-out period. Research access via compounding channels would end, leaving IND-based clinical trial supply as the primary remaining domestic access route.

Deferred or conditional recommendation: The committee may defer a compound pending additional data (often clinical safety or stability data), or recommend inclusion with restrictions on formulation type, strength, or prescribing context.

All seven compounds on the July agenda currently lack FDA-approved commercial equivalents — a condition that strengthens the clinical need argument for 503A inclusion but does not guarantee a favorable outcome, particularly where preclinical evidence is the primary evidence base.

What to watch for in the next 29 days

Docket submissions closing: Regulatory law practices following the PCAC docket typically submit public comment letters in the final 30 days before a hearing. The breadth and quality of submitted clinical need documentation, practitioner attestations, and literature summaries will influence how the committee weighs each nomination.

BPC-157 Phase 2 trial developments: NCT07437547 is currently enrolling; any data disclosure or site updates in the next 30 days could provide additional context for committee members reviewing the BPC-157 record.

Search volume acceleration: Based on historical PCAC hearing patterns, search volume for hearing-specific terms typically accelerates sharply in the final 2 weeks before the meeting date. Researchers and clinicians who want to follow the outcome in real time should bookmark the FDA PCAC July 2026 hub page, which will be updated with hearing outcomes when available.

Following the hearing

This site will publish an outcomes summary article — FDA PCAC July 2026 Hearing: Results and Implications — as soon as the committee's recommendations are made public, typically within 24–48 hours of the hearing's conclusion. Subscribe or bookmark that page for the fastest summary of which compounds received favorable and unfavorable recommendations.

For the full compound-by-compound analysis, all docket references, and the 503A regulatory framework explained in depth, see the FDA PCAC July 2026 Complete Hub.